Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma

OBJECTIVE: Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006. PATIENTS AND METHODS: Analysis involved patients who received ≥1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were progression-free before day...

Descripción completa

Detalles Bibliográficos
Autores principales: Robert, Caroline, Hwu, Wen-Jen, Hamid, Omid, Ribas, Antoni, Weber, Jeffrey S., Daud, Adil I., Hodi, F. Stephen, Wolchok, Jedd D., Mitchell (Gangadhar), Tara C., Hersey, Peter, Dronca, Roxana, Joseph, Richard W., Boutros, Celine, Min, Le, Long, Georgina V., Schachter, Jacob, Puzanov, Igor, Dummer, Reinhard, Lin, Jianxin, Ibrahim, Nageatte, Diede, Scott J., Carlino, Matteo S., Joshua, Anthony M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388128/
https://www.ncbi.nlm.nih.gov/pubmed/33360855
http://dx.doi.org/10.1016/j.ejca.2020.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388128/
https://www.ncbi.nlm.nih.gov/pubmed/33360855
http://dx.doi.org/10.1016/j.ejca.2020.11.010

Ejemplares similares